LP-211 is a selective and blood−brain barrier penetrant 5-HT 7 receptor agonist, with a K i of 0.58 nM, with high selectivity over 5-HT 1A receptor (K i , 188 nM) and D 2 receptor (K i , 142 nM).In VitroLP-211 is a selective 5-HT 7 receptor agonist,
LP-211 is a selective and blood−brain barrier penetrant 5-HT 7 receptor agonist, with a K i of 0.58 nM, with high selectivity over 5-HT 1A receptor (K i , 188 nM) and D 2 receptor (K i , 142 nM).In VitroLP-211 is a selective 5-HT 7 receptor agonist,
LP-211 is a selective and blood−brain barrier penetrant 5-HT 7 receptor agonist, with a K i of 0.58 nM, with high selectivity over 5-HT 1A receptor (K i , 188 nM) and D 2 receptor (K i , 142 nM).In VitroLP-211 is a selective 5-HT 7 receptor agonist,
LP-211 is a selective and blood−brain barrier penetrant 5-HT 7 receptor agonist, with a K i of 0.58 nM, with high selectivity over 5-HT 1A receptor (K i , 188 nM) and D 2 receptor (K i , 142 nM).In VitroLP-211 is a selective 5-HT 7 receptor agonist,
InformationARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and
InformationARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and
InformationARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and
InformationARV-771 is a potent pan-(bromodomain and extra-terminal)BET degrader, a novel BET-PROTAC(proteolysis-targeting chimera) with Kd of 34 nM, 4.7 nM, 8.3 nM, 7.6 nM, 9.6 nM, and 7.6 nM for BRD2(1), BRD2(2), BRD3(1), BRD3(2), BRD4(1), and